Related Experiment Videos
SR-121463. Sanofi-Synthélabo.
1Hospital Bellvitge CSUB, University of Barcelona, Spain. 9349amc@webcmb.comb.es
Current Opinion in Investigational Drugs (London, England : 2000)
|March 14, 2002
Summary
Sanofi-Synthélabo is developing SR-121463, a vasopressin V1 receptor antagonist, for cardiovascular conditions like heart failure and hypertension. This drug candidate has progressed to Phase IIa clinical trials for these indications.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Drug Development
Background:
- Sanofi-Synthélabo is developing SR-121463, a novel vasopressin V1 receptor antagonist.
- The compound is being investigated for potential cardiovascular applications, including congestive heart failure (CHF) and hypertension.
Purpose of the Study:
- To evaluate the efficacy and safety of SR-121463 in patients with cardiovascular indications.
- To advance the development of SR-121463 through clinical trials for CHF and hypertension.
Main Methods:
- SR-121463 has undergone Phase I clinical trials for CHF and hypertension.
- The drug candidate entered Phase IIa trials for these cardiovascular indications by September 2001.
Main Results:
- Development for glaucoma has been discontinued.
- Clinical trials are ongoing for congestive heart failure and hypertension.
Conclusions:
- SR-121463 shows potential as a treatment for cardiovascular diseases.
- Further clinical evaluation is necessary to determine the therapeutic value of SR-121463.